Limited populationbased information is available on the co-occurrence of dementia and PD. However, projecting the prevalence of PD with and without dementia during the next 50 years is crucial for planning public-health and patientcare initiatives. Objectives: The objective of this study was to project the prevalence of PD with and without dementia in the United States by 2060. Methods: We used the Rochester Epidemiology Project medical records-linkage system to identify all persons with PD with or without dementia residing in Olmsted County, Minnesota, on January 1, 2006. A movement disorders specialist reviewed the complete medical records of each person to confirm the presence of PD. We calculated the age-and sex-specific prevalence of PD with and without dementia and projected U.S. prevalence through 2060. Results: We identified 296 persons with PD with and without dementia on the prevalence date (187 men, 109 women); the overall prevalence increased with age from 0.01% (30-39 years) to 2.83% (90 years). The prevalence of PD without dementia increased with age from 0.01% (30-39 years) to 1.25% (90 years). The prevalence of PD with dementia increased with age from 0.10% (60-69 years) to 1.59% (90 years). The prevalence was higher in men than in women for all subtypes and all age groups. We project by 2060 an approximate doubling of the number of persons with PD without dementia and a tripling of the number of persons with PD with dementia in the United States. Conclusions: The prevalence of PD with and without dementia increases with age and is higher in men than women. We project that the number of persons with PD in the United States will increase substantially by 2060. PD is the second most common neurodegenerative disorder after Alzheimer's disease. The incidence of PD has been reported to be 14.2 per 100,000 personyears overall, to be higher in men than in women, and to increase with age.
PD is the second most common neurodegenerative disorder after Alzheimer's disease. The incidence of PD has been reported to be 14.2 per 100,000 personyears overall, to be higher in men than in women, and to increase with age. 1 According to a 2014 metaanalysis, the prevalence of PD increases with older age, from 41 per 100,000 (0.04%) in persons aged 40 to 49 years to 1,903 per 100,000 (1.9%) in persons aged 80 years and older. 2 Two studies have projected a dramatic increase in the number of persons living with PD and dementia with Lewy bodies (DLB) in the coming years, 3, 4 and 1 study projected a significant economic burden of patients with PD in the United States. 5 Earlier recognition and better therapeutic management of the clinical symptoms of PD have increased the prevalence of PD in recent years because of improved survival. The somewhat inconsistent results across several prevalence studies can be explained by the different clinical criteria used to diagnose PD. On the other hand, the studies converge on reporting a lower prevalence of PD in women and in Asia. 2 Of note, there is limited information on the prevalence of PD with dementia (PDD), DLB, and PD with other dementia (PD/OD). These data are crucial to understand the impact of PD-with and without dementia-on public health.
------------------------------------------------------------
To address questions regarding the burden of PD with and without dementia in the aging population, we calculated its prevalence on January 1, 2006, in Olmsted County, Minnesota, and we projected the number of persons affected by PD from 2015 to 2060 in the United States.
Methods

Ascertainment of Patients With Parkinsonism
Details about the ascertainment of parkinsonism patients are reported elsewhere. 1, 6 Briefly, we used the medical records-linkage system of the Rochester Epidemiology Project to identify all persons with parkinsonism residing in Olmsted County, Minnesota, between 1976 and 2010. The Rochester Epidemiology Project essentially indexes and links all medical information for the county population. [7] [8] [9] [10] All medical diagnoses, surgical interventions, and other procedures are available as computerized indexes using the Hospital Adaptation of the International Classification of Diseases, Eighth Revision 11 and the International Classification of Diseases, Ninth Revision.
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We ascertained potential cases of parkinsonism using a computerized-screening phase and a subsequent clinical-confirmation phase as described in the original two incidence studies for the periods 1976 to 1990 and 1991 to 2005. 1, 13 The complete medical records of all persons receiving at least 1 screening diagnostic code for parkinsonism were reviewed by a movement disorders specialist (JHB and RS) using specifically designed abstracting forms and instruction manuals. The movement disorders specialist established the onset year and type of parkinsonism using specified diagnostic criteria. 1, [13] [14] [15] [16] Further details about the case-finding procedures are published elsewhere. 1, 13 For this study, we identified all persons affected by PD with or without dementia alive and residing in Olmsted County, Minnesota, on January 1, 2006. Because we selected our prevalence day (January 1, 2006) at the end of a combined-incidence study period from 1976 to 2005, we included all persons with incident PD during the 30 years who survived to the prevalence day. In addition, we included persons who developed PD while living outside of Olmsted County but resided in the county on the prevalence day. These persons were not included in the incidence studies but were eligible for this prevalence study. The institutional review boards of the Mayo Clinic (Rochester, Minnesota) and Olmsted Medical Center (Rochester, Minnesota) approved the study.
Diagnostic Criteria
Our diagnostic adjudication included the following 2 steps: the definition of parkinsonism as a syndrome and the definition of different types of parkinsonism within the syndrome. We defined parkinsonism as the presence of at least 2 of the following 4 cardinal signs: rest tremor, bradykinesia, rigidity, and impaired postural reflexes. Among persons fulfilling the parkinsonism criteria, we applied diagnostic criteria for specific types of parkinsonism and grouped parkinsonism patients into presumed proteinopathies. 6 PD was defined as parkinsonism with all 3 of the following: no other cause (eg, repeated stroke with stepwise progression, repeated head injury, history of encephalitis, neuroleptic treatment within 6 months before symptom onset, hydrocephalus, brain tumor); no documented unresponsiveness to levodopa at doses of at least 1 g/d in combination with carbidopa (applicable only to treated patients); and no prominent or early (<1 year of onset) signs of more extensive nervous system involvement (eg, dysautonomia) not explained otherwise. 13 We used previously published consensus criteria to define DLB, PDD, and PD/OD (Table 1) . 1, 6, 17, 18 To determine whether a person had dementia on the prevalence day, he/she had to fulfill 1 of the following 2 criteria: (1) a physician diagnosis of dementia before prevalence day or (2) documentation in the medical record of loss of independence in everyday activities clearly related to cognitive difficulties (not motor), not in the context of delirium or other mental disorder, occurring before the prevalence day.
The case-finding procedures were valid and reliable as described more extensively elsewhere. 1, 13 In brief, an independent records review by the 2 movement disorders specialists applying the same diagnostic criteria (JHB and RS) showed 90% agreement on the presence of parkinsonism and 70% agreement on the exclusion of parkinsonism (j 5 0.60; 95% confidence interval [CI], 0.31-0.89; sample classified by RS as 30 patients with parkinsonism and 10 persons free of parkinsonism from the 1991-2005 incidence study). 1 In general, the agreement on the year of onset of parkinsonism was also high (intraclass correlation coefficient, 0.85; 95% CI, 0.77-0.92). 1 Finally, a comparison of clinical diagnoses of specific proteinopathies (synucleinopathies and tauopathies) with autopsy findings in the 65 patients who had died showed 81.5% overall agreement. 1 For synucleinopathies, the sensitivity was 97.8% (95% CI, 88.5-99.9), the specificity was 42.1% (95% CI, 20.3-66.5), the positive predictive value (PPV) was 80.4% (95% CI, 67.6-89.8), and the negative predictive value was 88.9% (95% CI, 51.8-99.7). For tauopathies, (11) Directly standardized to the total 2010 U.S. Census population. The prevalence directly standardized by age and by sex to the total 2010 U.S. Census population was 0.24 for all types of PD, 0.15 for PD without dementia, 0.09 for PD with dementia, 0.04 for PDD, 0.04 for DLB, and 0.01 for PD/OD. 
Data Analysis
We chose January 1, 2006, as our prevalence date and excluded persons who denied authorization to use their medical records for research. 10 We included all persons who met the criteria for PD with or without dementia, had symptom onset before the prevalence date, and resided in Olmsted County on the prevalence date.
We computed age-and sex-specific prevalence for PD overall and for specific subtypes of PD. Because our study was descriptive and involved the entire Olmsted County population, no sampling procedures were involved, and statistical tests were not necessary for the interpretation of the data. Prevalence was directly standardized by age and by sex to the 2010 U.S. Census population (when applicable), and projections were made using age-and sex-specific prevalence and U.S. population estimates available from the U.S. Census. 19 All analyses used SAS version 9.4 (SAS Institute Inc., Cary, North Carolina). Table 2 shows the results of the prevalence of PD, PDD, DLB, PD/OD, and all types of PD combined. We identified 296 persons with prevalent PD of all types; 187 (63.2%) were men, and 109 (36.8%) were women. The overall prevalence increased with age from 0.01% (30-39 years) to 2.83% (90 years and older). The prevalence of PD without dementia increased with age from 0.01% (30-39 years) to 1.25% (90 years and older). The prevalence of PD with dementia increased with age from 0.10% (60-69 years) to 1.59% (90 years and older; Fig. 1 ).
Results
The overall prevalence was 0.03% (43 persons) for DLB and 0.04 (54 persons) for PDD; in both subtypes, 
S A V I C A E T A L
men were more commonly affected than women, and the prevalence increased with older age. However, there was a small decline in the prevalence of PDD, DLB, and all types of PD with dementia in women 90 years old and older. The proportion of PD patients with dementia increased with older age (Fig. 2) . The prevalence of PD was higher in men than in women for all subtypes of PD and across all ages. Table 3 shows the prevalence of PD overall and by subtypes for 6 segments of the population with a 10-year moving age cut-off: persons 40, 50, 60, 70, 80, and 90 years of age. The prevalence of PD increased with age, and men were affected more than women. In particular, the prevalence of all types of PD was 1.3% for age 60, 2.0% for age 70 years, and 2.8% for age 90 years. Figure 3 shows the projected number of persons with PD of all types and PD with dementia from 2015 to 2060 in the United States. We project that the number of persons living with PD of all types will increase significantly from approximately 866,000 persons in 2015 to 1.96 million by 2060 (a 2.26 times increase; approximately a doubling). During the same time period, we project that the number of persons living with PD with dementia (PDD, DLB, and PD/OD) will increase from 312,000 persons in 2015 to 810,000 by 2060 (a 2.60 times increase; approximately a tripling).
Discussion
Our study suggests that the prevalence of PD without dementia and of PD with dementia (PDD, DLB, and PD/OD) increases with older age and is more common in men than women. We project the number of persons with PD of all types to approximately double and the number of persons with PD with dementia to approximately triple by 2060 in the United States.
Our findings are consistent with the findings from a recent meta-analysis comparing the prevalence of PD across several studies. 2 The prevalence of PD was reported to increase from 41 per 100,000 (0.04%) in persons aged 40 to 49 years to 1,903 per 100,000 (1.9%) for persons aged 80 years older. In addition, the meta-analysis showed geographical differences with lower prevalence of PD in Asia when compared with Europe, North America, and Australia. 2 The use of different clinical criteria may explain some of the variability in prevalence estimates. 2 The 
use of different diagnostic criteria may account for up to a 36% change in the identification of cases. 20 Similarly, variability may be a result of different medical personnel making the diagnosis of PD (eg, specialists vs general practitioners). Interestingly, although major methodological differences are present in different studies, some epidemiological patterns are consistent. The prevalence of PD increases consistently with older age, and prevalence is consistently higher in men than women across almost all studies. 2 The prevalence of PD with dementia (including PDD, DLB, and PD/OD) has not been as extensively studied as the prevalence of PD without dementia. Studies have likely been hampered by difficulties in the identification of cases because of complex clinical criteria and by the limited access to complete records. DLB has been reported as the second most common type of degenerative dementia, accounting for approximately 10% to 15% of autopsy cases. 21 However, in population-based studies of the elderly (aged 65 years and older), the prevalence of DLB has varied widely from 0.1% 22, 23 to 30.5% of the population. 24, 25 The prevalence of DLB increases with age and affects men more than women. Limited and unstable prevalence data are available for PDD and PD/OD.
Our study supports previous reports projecting a major increase in the number of persons living with PD in the United States in the coming years. The pivotal study by Dorsey and colleagues 3 predicted that the number of persons living with PD (aged 50 years or older) in the 15 most populous countries was between 4.1 and 4.6 million in 2005 and would double to between 8.7 and 9.3 million by 2030. Similarly, a more recent study projected substantial increases in the number of persons living with PD in the United States, Canada, and Europe by 2050. 4 This more recent study also projected that DLB (a subtype of PD with dementia) would have greater percent increases than PD. We projected similar increases (nearly a triplication) in the number of persons living with PD associated with dementia.
The aging of the population, the improved management of PD, and the development of disease-modifying agents (leading to prolonged survival) are likely to affect the projected increase in the number of persons affected by PD during the next several decades. However, a recent study by our group reported worse survival in persons with DLB and PDD than in persons with PD without dementia. 26 In addition, there may be other factors contributing to increased prevalence beyond the aging of the population and improved treatment and survival. It is also plausible that the future introduction of preventive interventions or environmental and social changes may decrease the incidence of PD and related disorders. However, we have recently reported an increase in the incidence of PD over 30 years in this same Olmsted County population. 27 If this trend is confirmed in other U.S. populations, the projections should be modified accordingly. 27 Our study has several strengths. First, our study explored PD without dementia and PD with dementia of all types combined (including PDD, DLB, and PD/ OD) and also separately. Therefore, we were able to provide novel information beyond the pooled definition of all PD. Second, we studied a relatively stable population using a population-based, medical recordslinkage system encompassing nearly all care facilities in Olmsted County, Minnesota. A movement disorders specialist adjudicated all persons by reviewing their complete medical records to reduce differences over time in diagnostic criteria.
Our study also has limitations. First, assessing the precise chronology of symptoms and the time of onset of clinical features from an historical review of medical records was difficult for some patients. Second, cases of DLB presenting without parkinsonian symptoms were not identified by our methods. However, given that parkinsonism is present in the majority of patients with DLB, especially after some years into the disease process, we likely captured most persons living with DLB. Last, our projections assume that the incidence of PD will remain stable to 2060. This assumption may result in our prevalence projections being either underestimated (if the incidence is truly increasing) or overestimated (if the incidence will decrease as a result of new preventive interventions or environmental and social changes introduced before 2060).
Conclusions
We found that the prevalence of PD overall and of PD with dementia increases with age and affects men more than women. In addition, we projected a dramatic increase in the number of persons with PD living in the United States through 2060. Our study contributes important new projections for the future burden of PD and, in particular, for PD with dementia. These projections have important public health implications.
